| Impact of FDG PET-CT imaging on the decision making in the biologic suspicion of ovarian carcinoma recurrence. | |
| | |
MedLine Citation:
|
PMID: 17961640 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: The aim of this prospective study was to evaluate the impact of integrated PET-CT on treatment management in ovarian carcinoma recurrence suspicion because of increased CA-125. METHODS: Twenty-nine patients (mean age=61 years), initially treated for ovarian carcinoma (FIGO stage I n=2, stage II n=3, stage III n=21 and stage IV n=3), presenting with increased CA-125 (mean=160 IU/ml, range 33-1930), underwent subsequently a CT and a PET-CT scans. The recurrence was acknowledged by the referring physicians for all patients. The impact of PET-CT on patient's management was evaluated by comparing the therapeutic decision mentioned respectively on the pre and post PET-CT questionnaires filled in by the oncologists. RESULTS: The CT scan was positive in 22/29 patients (76%) and negative in 7/29 patients (24%). The PET-CT scan was positive in 27/29 patients (93%) and negative in 2/29 (7%) patients. Five out of the seven patients with a negative CT scan had a positive PET-CT scan. In comparison to CT scan alone, the PET-CT scan modified the disease distribution for 16 patients (55%; p<0.001) in the following ways: more advanced disease (n=11), more limited disease (n=4), and different localizations (n=1). The assessment of pre and post PET-CT questionnaires showed a statistically significant change in the decision making for 10 patients (34%, p<0.0001). CONCLUSION: This questionnaire-based study showed that PET-CT imaging allows a better restaging than CT and induces a change in clinical management in over one third of patients with suspected ovarian carcinoma recurrence on increased CA-125. |
| | |
Authors:
|
Michael Soussan; Myriam Wartski; Pascal Cherel; Emmanuelle Fourme; Alain Goupil; Elise Le Stanc; Nasrine Callet; Jérôme Alexandre; Alain-Paul Pecking; Jean-Louis Alberini |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't Date: 2007-10-24 |
Journal Detail:
|
Title: Gynecologic oncology Volume: 108 ISSN: 1095-6859 ISO Abbreviation: Gynecol. Oncol. Publication Date: 2008 Jan |
Date Detail:
|
Created Date: 2007-12-31 Completed Date: 2008-01-15 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0365304 Medline TA: Gynecol Oncol Country: United States |
Other Details:
|
Languages: eng Pagination: 160-5 Citation Subset: IM |
Affiliation:
|
Nuclear Medicine Department, Rene Huguenin Cancer Research Center, Saint-Cloud, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over CA-125 Antigen / blood Decision Making Female Fluorodeoxyglucose F18 / diagnostic use* Humans Middle Aged Neoplasm Recurrence, Local / blood, radionuclide imaging*, therapy Ovarian Neoplasms / blood, radionuclide imaging*, therapy Prospective Studies Questionnaires Radiopharmaceuticals / diagnostic use* Tomography, X-Ray Computed |
| Chemical | |
Reg. No./Substance:
|
0/CA-125 Antigen; 0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Localization of myosin II regulatory light chain in the cerebral vasculature.
Next Document: Leptomeningeal dissemination of ovarian carcinoma through a ventriculoperitoneal shunt.